Formation Bio, an AI-native pharma company, today announced the appointment of Michael D. Ehlers, MD, PhD, as Chief Scientific Officer (CSO) and Head of Research & Development (R&D). Ehlers will ...
Patient nonadherence rates of 30%–50% are linked to dosing complexity and poor acceptability, motivating patient-centered formulation strategies, especially for pediatrics and older adults. A ...
Data-driven genomic mapping is the ‘future of tailored, bespoke medicine’ ...
India's BRICS health agenda could create opportunities for pharma, digital health and AI firms, but market access remains the ...
Significant advances have been made in the development of patient-derived tumor "organoids" for preclinical research in two ...
Dr. Erica Schwartz told the Senate health committee she "will never betray the science" and pledged to use "radical ...
As the United States marks its 250th anniversary, WTOP presents “250 Years of America,” a multipart series examining the innovations, breakthroughs and pivotal moments that have shaped the nation ...
Global Quantum Forum 2026 opens in Chicago as Trump's post-quantum cryptography executive orders set 2030 and 2031 deadlines ...
Pain in the Arsenal on MSN
What Went Wrong With Jack Wilshere? And Has Arsenal Finally Learned From It?
A sports science analysis of Jack Wilshere's injury history, workload, stress fracture and whether Arsenal's modern approach ...
The Trump administration’s latest nominee to lead the nation’ top public health agency drew frustrated reactions from some ...
Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next. The biggest obstacle to translating retina’s technology ...
The revolving-door leadership of the nation’s top public health agency took another potential turn on Wednesday, as Dr. Erica ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results